Bank Of Montreal Editas Medicine, Inc. Transaction History

Bank Of Montreal

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 13, 2024	BUY	$7.03 - $11.53 $86,961 - $142,626	12,370 New	12,370 $89,000
Q3 2022 Nov 10, 2022	SELL	$12.16 - $19.42 $130,294 - $208,085	-10,715 Reduced 22.53%	36,852 $468,000
Q2 2022 Aug 11, 2022	SELL	$9.99 - $21.35 $40,119 - $85,741	-4,016 Reduced 7.79%	47,567 $655,000
Q1 2022 May 12, 2022	BUY	$14.08 - $27.63 $726,288 - $1.43 Million	51,583 New	51,583 $1.01 Million
Q4 2021 Feb 11, 2022	SELL	$26.55 - $40.57 $227,799 - $348,090	-8,580 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$39.27 - $72.94 $336,936 - $625,825	8,580 New	8,580 $365,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.